|
News | Press Releases
| 02/27/08 - |
M. Scott Harris, M.D., joins Ocera Therapeutics, Inc., as Chief Medical Officer |
| 02/20/08 - |
Ocera Therapeutics Closes $35.5 Million Series C Financing
[BioWorld Today- Feb. 20, 2008]
[FierceBiotech - Feb. 22, 2008]
|
| 01/07/08 - |
Ocera Therapeutics Receives Orphan Drug Status for AST-120 for Pouchitis |
| 10/15/07 - |
Ocera Therapeutics Announces Positive Results with AST-120 in Pouchitis |
| 10/08/07 - |
Ocera Therapeutics, Inc. Completes Enrollment in FHAST1 , a Pivotal Phase 3 Clinical Trial in Fistulizing Crohn’s Disease |
| 09/19/07 - |
Ocera Therapeutics, Inc. Initiates Phase 2 Clinical Trial in Irritable Bowel Syndrome |
| 09/19/07 - |
Ocera Therapeutics, Inc. Initiates Phase 2 Clinical Trial in Hepatic Encephalopathy |
| 07/10/06 - |
Ocera Therapeutics, Inc. Raises $12 Million Series B Financing |
| 05/24/06 - |
Ocera Therapeutics Initiates Phase 3 Trial in Fistulizing Crohn’s disease |
| 03/26/06 - |
Ocera Therapeutics Initiates Phase 2 Trial for Active Pouchitis |
| 03/01/06 - |
Ocera Therapeutics, Inc, appoints Joseph Davie, M.D., Ph.D., former head of Biogen Research to its Board of Directors |
| 01/17/06 - |
Ocera Therapeutics, Inc., A New Gastrointestinal and Liver-Focused Company, raises $14.5M in Series A Financing |
|
|
